CTRI/2023/10/059345招募中3 期
A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder - NI
试验速览
- 阶段
- 3 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Provides written informed consent
- •2. Male or female patients between the ages 18 and 65 years, inclusive
- •3. Meets Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT), and meet all the following criteria:
- •a. The start of the current MDE is at least 8 weeks but no more than 18 months prior to Screening (Visit 1)
- •b. Has at least moderate severity of illness based on rater administered MADRS total score = 24 at Screening (Visit 1) and at Baseline (Visit 2)
- •c. Has at least moderate severity of illness based on CGI-S score = 4 at Screening (Visit 1) and at Baseline (Visit 2)
- •d. Has a QIDS-SR-16 score = 14 at Screening (Visit 1) and at Baseline (Visit 2)
- •e. Has sufficient history and medical record confirmation (as defined in the Study Reference Manual) verifying ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning.
- •4. Currently having an inadequate response to ADT (less than 50% improvement) as confirmed by the Investigator using theATRQ and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration and:
- •a. citalopram/escitalopram
- •b. fluoxetine
- •c. paroxetine
- •d. sertraline
- •e. duloxetine
- •f. levomilnacipran/milnacipran (if locally approved for MDD)
- •g. venlafaxine/desvenlafaxine
- •h. bupropion
- •i. vilazodone
- •j. vortioxetine
排除标准
- •1. Within the patient’s lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:
- •a. Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder
- •b. Bipolar disorder
- •2. Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:
- •a. Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD,
- •provided these symptoms do not require concurrent treatment
- •b. Eating disorder
- •c. Substance use disorders (excluding nicotine)
- •d. Personality disorder of sufficient severity to have a major impact on the patient’s psychiatric status;
- •e. Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment;
- •3. The patient experiences a = 25% decrease in the MADRS total score between Screening (Visit 1) and Baseline (Visit 2)
- •4. The patient experiences a = 25% decrease in the QIDS-SR-16 total score between Screening (Visit 1) and Baseline (Visit 2)
- •5. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:
- •a. At Screening (Visit 1), the patient scores yes ? on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline (Visit 2), the patient scores yes ? on Suicidal Ideation Items 4 or 5 since the Screening Visit
- •b. At Screening (Visit 1), the patient has had 1 or more suicide attempts within 2 years prior to Screening
- •c. At Screening (Visit 1) or Baseline (Visit 2), the patient scores = 5 on MADRS Item 10 (Suicidal Thoughts), or
- •d. The patient is considered to be in imminent danger to him/herself or others.
- •6. The patient has a first MDE at age 60 years or older.
研究者
相似试验
招募中
3 期
A study to assess the effectiveness and safety of Lumateperone as another treatment used together with the primary treatment in the Treatment of Patients with Major Depressive DisorderCTRI/2023/04/051968Intra-Cellular Therapies, Inc
招募中
1 期
A study to assess the efficacy and safety of lumateperone in patients with major depressive disorderMedDRA version: 21.1Level: LLTClassification code: 10081270Term: Major depressive disorder Class: 10037175Major Depressive DisorderCTIS2023-503836-41-00Intra-Cellular Therapies Inc.470
招募中
3 期
Clinical study of cannabidiol in children, adolescents and young adults with Fragile X syndrome (RECONNECT)Fragile X SyndromeHuman Genetics and Inherited Disorders - Other human genetics and inherited disordersNeurological - Other neurological disordersACTRN12621000874819Zynerba Pharmaceuticals Pty Ltd204
进行中（未招募）
1 期
A Study to Assess the Efficacy and Safety of Lumateperone as Add on Therapy in the Treatment of Patients with Major Depressive DisorderMedDRA version: 20.0Level: LLTClassification code 10025458Term: Major depressive disorder, recurrent episode, moderate degreeSystem Organ Class: 100000004873MedDRA version: 21.1Level: LLTClassification code 10081270Term: Major depressive disorderSystem Organ Class: 100000004873Major Depressive DisorderEUCTR2021-001212-29-BGIntra-Cellular Therapies, Inc.470
进行中（未招募）
1 期
A Study to Assess the Efficacy and Safety of Lumateperone as Add on Therapy in the Treatment of Patients with Major Depressive DisorderMajor Depressive DisorderEUCTR2021-001192-17-CZIntra-Cellular Therapies, Inc.470